Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

Cancer Cell

Volumn 10, Issue 4, 2006, Pages 331-342

  Wei, Guo ^a,b   Twomey, David ^a,b   Lamb, Justin ^b   Schlis, Krysta ^a   Agarwal, Jyoti ^a   Stam, Ronald W ^c   Opferman, Joseph T ^d   Sallan, Stephen E ^a   den Boer, Monique L ^c   Pieters, Rob ^c   Golub, Todd R ^a,b   Armstrong, Scott A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CELLCYCLE

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN MCL 1; RAPAMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHEMICAL GENETICS; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENETIC SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURAL GENOMICS;

EID: 33749443714     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.09.006     Document Type: Article

References (61)

1. Abrams M.T., Robertson N.M., Yoon K., and Wickstrom E. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J. Biol. Chem. 279 (2004) 55809-55817
2. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 (2003) 173-183
3. Bachmann P.S., Gorman R., Mackenzie K.L., Lutze-Mann L., and Lock R.B. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 105 (2005) 2519-2526
4. Bouillet P., Metcalf D., Huang D.C., Tarlinton D.M., Kay T.W., Kontgen F., Adams J.M., and Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286 (1999) 1735-1738
5. Buckhaults P. Gene expression determinants of clinical outcome. Curr. Opin. Oncol. 18 (2006) 57-61
6. Certo M., Moore Vdel G., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., and Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365
7. Chao D.T., Linette G.P., Boise L.H., White L.S., Thompson C.B., and Korsmeyer S.J. Bcl-XL and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182 (1995) 821-828
8. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., and Huang D.C.S. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17 (2005) 393-403
9. Danial N.N., and Korsmeyer S.J. Cell death: Critical control points. Cell 116 (2004) 205-219
10. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Korholz D., Graubner U., Haas R.J., Jorch N., Spaar H.J., et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J. Clin. Oncol. 21 (2003) 3262-3268
11. Domen J., Cheshier S.H., and Weissman I.L. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J. Exp. Med. 191 (2000) 253-264
12. Dordelmann M., Reiter A., Borkhardt A., Ludwig W.D., Gotz N., Viehmann S., Gadner H., Riehm H., and Schrappe M. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94 (1999) 1209-1217
13. Erlacher M., Michalak E.M., Kelly P.N., Labi V., Niederegger H., Coultas L., Adams J.M., Strasser A., and Villunger A. BH3-only proteins Puma and Bim are rate-limiting for γ-radiation and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106 (2005) 4131-4138
14. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 (2005) 876-885
15. Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15 (2001) 807-826
16. Grillot D.A., Merino R., and Nunez G. Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J. Exp. Med. 182 (1995) 1973-1983
17. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
18. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
19. Hartmann B.L., Geley S., Loffler M., Hattmannstorfer R., Strasser-Wozak E.M., Auer B., and Kofler R. Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Oncogene 18 (1999) 713-719
20. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
21. Heuser M., Wingen L.U., Steinemann D., Cario G., von Neuhoff N., Tauscher M., Bullinger L., Krauter J., Heil G., Dohner H., et al. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 90 (2005) 1484-1492
22. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J., Kazemier K.M., Pei D., Cheng C., Pui C.H., Relling M.V., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351 (2004) 533-542
23. Hongo T., Yajima S., Sakurai M., Horikoshi Y., and Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89 (1997) 2959-2965
24. Kaspers G.J., Veerman A.J., Pieters R., Van Zantwijk C.H., Smets L.A., Van Wering E.R., and Van Der Does-Van Den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90 (1997) 2723-2729
25. Kaspers G.J., Pieters R., Van Zantwijk C.H., Van Wering E.R., Van Der Does-Van Den Berg A., and Veerman A.J. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood 92 (1998) 259-266
26. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., and Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 7 (2005) R1097-R1110
27. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., and Newmeyer D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17 (2005) 525-535
28. Lamb J., Ramaswamy S., Ford H.L., Contreras B., Martinez R.V., Kittrell F.S., Zahnow C.A., Patterson N., Golub T.R., and Ewen M.E. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114 (2003) 323-334
29. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.-P., Subramanian A., Ross K.N., et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) in press
30. Li C., and Wong W.H. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA 98 (2001) 31-36
31. Lindsten T., Ross A.J., King A., Zong W.X., Rathmell J.C., Shiels H.A., Ulrich E., Waymire K.G., Mahar P., Frauwirth K., et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6 (2000) 1389-1399
32. Liu H., Perlman H., Pagliari L.J., and Pope R.M. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-κB, Bad, or caspase activation. J. Exp. Med. 194 (2001) 113-126
33. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
34. Marimpietri D., Nico B., Vacca A., Mangieri D., Catarsi P., Ponzoni M., and Ribatti D. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 24 (2005) 6785-6795
35. Maurer U., Charvet C., Wagman A.S., Dejardin E., and Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21 (2006) 749-760
36. Memon S.A., Moreno M.B., Petrak D., and Zacharchuk C.M. Bcl-2 blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T cell hybridoma. J. Immunol. 155 (1995) 4644-4652
37. Mintz M.B., Sowers R., Brown K.M., Hilmer S.C., Mazza B., Huvos A.G., Meyers P.A., Lafleur B., McDonough W.S., Henry M.M., et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 65 (2005) 1748-1754
38. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., and Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10 (2004) 7031-7042
39. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., and Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 17 (2003) 1475-1486
40. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
41. Opferman J.T., and Korsmeyer S.J. Apoptosis in the development and maintenance of the immune system. Nat. Immunol. 4 (2003) 410-415
42. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., and Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426 (2003) 671-676
43. Opferman J.T., Iwasaki H., Ong C.C., Suh H., Mizuno S., Akashi K., and Korsmeyer S.J. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307 (2005) 1101-1104
44. Peng T., Golub T.R., and Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol. 22 (2002) 5575-5584
45. Pieters R., Huismans D.R., Loonen A.H., Hahlen K., van der Does-van den Berg A., van Wering E.R., and Veerman A.J. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338 (1991) 399-403
46. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7 (1995) 541-546
47. Schmidt S., Rainer J., Riml S., Ploner C., Jesacher S., Achmuller C., Presul E., Skvortsov S., Crazzolara R., Fiegl M., et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 107 (2006) 2061-2069
48. Sentman C.L., Shutter J.R., Hockenbery D., Kanagawa O., and Korsmeyer S.J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67 (1991) 879-888
49. Siegel R.M., Katsumata M., Miyashita T., Louie D.C., Greene M.I., and Reed J.C. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc. Natl. Acad. Sci. USA 89 (1992) 7003-7007
50. Stegmaier K., Ross K.N., Colavito S.A., O'Malley S., Stockwell B.R., and Golub T.R. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat. Genet. 36 (2004) 257-263
51. Strasser A., Harris A.W., and Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67 (1991) 889-899
52. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005) 15545-15550
53. Takeuchi O., Fisher J., Suh H., Harada H., Malynn B.A., and Korsmeyer S.J. Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proc. Natl. Acad. Sci. USA 102 (2005) 11272-11277
54. Tissing W.J., Meijerink J.P., den Boer M.L., and Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 17 (2003) 17-25
55. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
56. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., and Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302 (2003) 1036-1038
57. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., and Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 19 (1999) 6195-6206
58. Wang Z., Malone M.H., He H., McColl K.S., and Distelhorst C.W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J. Biol. Chem. 278 (2003) 23861-23867
59. Wei G., Guo J., Doseff A.I., Kusewitt D.F., Man A.K., Oshima R.G., and Ostrowski M.C. Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model. J. Immunol. 173 (2004) 1374-1379
60. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
61. Zhou P., Qian L., Bieszczad C.K., Noelle R., Binder M., Levy N.B., and Craig R.W. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92 (1998) 3226-3239